Although a recent clinical study argued that after examining all potential confounding factors, higher levels of anti-PCSK9 autoantibodies were significantly related to the increased deaths among diabetes patients,451 Evolocumab has been reported to significantly decrease the risk of recurring CVEs in patients with pre-existing ASCVD and/or T2D.452,453 The relative risk (RR) for the main outcome reduced by 15%, with a HR of 0.85 (95% CI 0.79–0.92) over a median 2.2-year monitoring period. Here, PCSK9 is linked to atherosclerosis.